Immunologic and Clinical Failure of Antiretroviral Therapy in People Living with Human Immunodeficiency Virus within Two Years of Treatment

Table 2

Predictors of treatment failure among people living with HIV in ACSH, Northern Ethiopia, 2017.

Variables		Treatment failure		AHR	95% CI	value
		No (%)	Yes (%)
ART regimen	Non-AZT-based	495 (67.3)	22 (62.9)	1	1	1
	AZT-based	240 (32.7)	13 (371)	16.95	3.02-95.1	0.001
Baseline CD4 count	≤200	539 (73.3)	26 (74.3)	1	1	1
	200-300	124 (16.9)	3 (8.6)	1.25	0.26-6.02	0.781
	≥301	72 (9.8)	6 (17.1)	0.199	0.05-0.76	0.018
Sex	Female	422 (57.4)	20 (57.1)	1	1	1
	Male	313 (42.6)	15 (42.9)	0.622	0.27-1.45	0.272
Baseline functional status	Ambulatory	185 (25.2)	18 (51.4)	1	1	1
	Working	474 (64.5)	13 (37.1)	1.04	0.29-3.47	0.995
	Bedridden	76 (10.3)	4 (11.4)	0.131	0.029-0.596	0.009
Baseline WHO stage	T1 and T2	208 (28.3)	2 (5.7)	1	1	1
	T3	391 (53.2)	19 (54.3)	0.915	0.155-5.4	0.922
	T4	136 (18.5)	14 (40)	3.4	0.42-27.52	0.251

Note: AHR: adjusted hazard ratio; CI: confidence interval; ART: antiretroviral therapy; WHO: World Health Organization; AZT: zidovudine. Statistical significance at .